Skelton Mike, Khokhar Waqqas Ahmad, Thacker Simon P
Department of Psychiatry, The University of Nottingham, Institute of Mental Health, Triumph Road, Nottingham, UK, NG7 2TU.
Cochrane Database Syst Rev. 2015 May 22;2015(5):CD009785. doi: 10.1002/14651858.CD009785.pub2.
Delusional disorder is commonly considered to be difficult to treat. Antipsychotic medications are frequently used and there is growing interest in a potential role for psychological therapies such as cognitive behavioural therapy (CBT) in the treatment of delusional disorder.
To evaluate the effectiveness of medication (antipsychotic medication, antidepressants, mood stabilisers) and psychotherapy, in comparison with placebo in delusional disorder.
We searched the Cochrane Schizophrenia Group's Trials Register (28 February 2012).
Relevant randomised controlled trials (RCTs) investigating treatments in delusional disorder.
All review authors extracted data independently for the one eligible trial. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis with a fixed-effect model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again with a fixed-effect model. We assessed the risk of bias of the included study and used the GRADE approach to rate the quality of the evidence.
Only one randomised trial met our inclusion criteria, despite our initial search yielding 141 citations. This was a small study, with 17 people completing a trial comparing CBT to an attention placebo (supportive psychotherapy) for people with delusional disorder. Most participants were already taking medication and this was continued during the trial. We were not able to include any randomised trials on medications of any type due to poor data reporting, which left us with no usable data for these trials. For the included study, usable data were limited, risk of bias varied and the numbers involved were small, making interpretation of data difficult. In particular there were no data on outcomes such as global state and behaviour, nor any information on possible adverse effects.A positive effect for CBT was found for social self esteem using the Social Self-Esteem Inventory (1 RCT, n = 17, MD 30.5, CI 7.51 to 53.49, very low quality evidence), however this is only a measure of self worth in social situations and may thus not be well correlated to social function. More people left the study early if they were in the supportive psychotherapy group with 6/12 leaving early compared to 1/6 from the CBT group, but the difference was not significant (1 RCT, n = 17, RR 0.17, CI 0.02 to 1.18, moderate quality evidence). For mental state outcomes the results were skewed making interpretation difficult, especially given the small sample.
AUTHORS' CONCLUSIONS: Despite international recognition of this disorder in psychiatric classification systems such as ICD-10 and DSM-5, there is a paucity of high quality randomised trials on delusional disorder. There is currently insufficient evidence to make evidence-based recommendations for treatments of any type for people with delusional disorder. The limited evidence that we found is not generalisable to the population of people with delusional disorder. Until further evidence is found, it seems reasonable to offer treatments which have efficacy in other psychotic disorders. Further research is needed in this area and could be enhanced in two ways: firstly, by conducting randomised trials specifically for people with delusional disorder and, secondly, by high quality reporting of results for people with delusional disorder who are often recruited into larger studies for people with a variety of psychoses.
妄想障碍通常被认为难以治疗。抗精神病药物经常被使用,并且人们越来越关注心理治疗(如认知行为疗法,CBT)在妄想障碍治疗中的潜在作用。
评估药物治疗(抗精神病药物、抗抑郁药、心境稳定剂)和心理治疗与安慰剂相比在妄想障碍治疗中的有效性。
我们检索了Cochrane精神分裂症研究组试验注册库(2012年2月28日)。
调查妄想障碍治疗方法的相关随机对照试验(RCT)。
所有综述作者独立为一项符合条件的试验提取数据。对于二分法数据,我们采用固定效应模型,在意向性分析的基础上计算风险比(RR)及其95%置信区间(CI)。在可能的情况下,我们计算了主要结局的说明性比较风险。对于连续性数据,我们同样采用固定效应模型计算平均差(MD)。我们评估了纳入研究的偏倚风险,并使用GRADE方法对证据质量进行评级。
尽管我们最初的检索得到了141篇文献,但只有一项随机试验符合我们的纳入标准。这是一项小型研究,有17人完成了一项将CBT与注意力安慰剂(支持性心理治疗)进行比较的试验,试验对象为患有妄想障碍的患者。大多数参与者已经在服用药物,并且在试验期间继续服用。由于数据报告不佳,我们未能纳入任何关于任何类型药物的随机试验,这使得我们没有这些试验的可用数据。对于纳入的研究,可用数据有限,偏倚风险各异,且涉及人数较少,使得数据解释困难。特别是没有关于整体状态和行为等结局的数据,也没有关于可能的不良反应的任何信息。使用社会自尊量表发现CBT对社会自尊有积极影响(1项RCT,n = 17,MD 30.5,CI 7.51至53.49,极低质量证据),然而这只是对社交情境中自我价值的一种衡量,因此可能与社会功能的相关性不强。如果在支持性心理治疗组,更多人提前退出研究,12人中有6人提前退出,而CBT组为6人中有1人提前退出,但差异不显著(1项RCT,n = 17,RR 0.17,CI 0.02至1.18,中等质量证据)。对于精神状态结局,结果存在偏差,难以解释,特别是考虑到样本量较小。
尽管在国际疾病分类系统(如ICD - 10和DSM - 5)中这种障碍已得到认可,但关于妄想障碍的高质量随机试验却很匮乏。目前没有足够的证据为妄想障碍患者的任何类型治疗提供循证推荐。我们所发现的有限证据不能推广到妄想障碍患者群体。在找到进一步的证据之前,提供对其他精神障碍有效的治疗方法似乎是合理的。该领域需要进一步的研究,可通过两种方式加强:第一,专门针对妄想障碍患者进行随机试验;第二,对经常被纳入各种精神病患者大型研究中的妄想障碍患者的结果进行高质量报告。